<DOC>
	<DOCNO>NCT00655707</DOCNO>
	<brief_summary>This prospective dose escalation study administration adult human stem cell patient end stage liver failure . Successive group two patient receive ascend dos autologous adult human stem cell start 1x10 [ 9 ] cell . Following expansion approve GMP facility cell infuse either hepatic artery portal vein research participant . The aim trial determine maximum tolerate dose autologous adult stem cell infuse either hepatic artery portal vein . The maximum dose would give would 5x10 ten [ 10 ] . To assess improvement liver function measure serological biochemical analysis determine whether symptomatic improvement report patient .</brief_summary>
	<brief_title>A Phase I/II Safety Tolerability Dose Escalation Study Autologous Stem Cells Patients With Liver Insufficiency</brief_title>
	<detailed_description />
	<mesh_term>Liver Diseases</mesh_term>
	<mesh_term>Hepatic Insufficiency</mesh_term>
	<criteria>Male female patient age 20 65 year age Evidence chronic liver insufficiency The presence abnormal serum albumin and/or bilirubin and/or prothrombin time Patient unlikely receive liver transplant Has WHO performance score le 2 Has life expectancy least 3 month Ability give write consent Women childbearing potential may include , must use reliable appropriate contraceptive method Patients age 20 age 65 year Pregnant lactating woman Patients recent recurrent GI bleed spontaneous bacterial peritonitis Patients evidence HIV life threaten infection Patients unable give write consent Patients history hypersensitivity GCSF Patients include clinical trial within previous month</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>June 2015</verification_date>
	<keyword>Adult stem cell therapy</keyword>
</DOC>